Drug Profile
Research programme: chronic obstructive pulmonary disease therapeutics - LTT Bio-Pharma
Alternative Names: LT-0302; mepenzolate bromide - LTT Bio-PharmaLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator LTT Bio-Pharma
- Class Anti-inflammatories; Bronchodilators; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in Japan
- 14 Aug 2015 LTT Bio-Pharma has international patent protection for COPD therapeutics
- 13 Aug 2015 Early research in Chronic obstructive pulmonary disease in Japan before august 2015 (unspecified route)